Aelix Therapeutics raises $13M for therapeutic HIV vaccine
By Cormac Sheridan
Tuesday, January 12, 2016
DUBLIN The latest contender to emerge from Spain's fledgling biotech sector is Aelix Therapeutics SL, which has raised €11.5 (US$12.6 million) in a series A round to fund clinical development of a therapeutic vaccine for HIV infection.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.